Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Farnesylthiosalicylic acid blocks kinase triggers in breast cancer cells
December 29th, 2005
Farnesylthiosalicylic acid (FTS) blocks kinase triggers in breast cancer cells. "Estradiol (E-2) stimulates proliferation of hormone-dependent breast cancer and exerts downstream effects on growth factors and their receptors. Key among the pathways' mediating growth factor action is the MAP kinase signaling cascade and the PI-3 kinase pathway with its downstream effector mTOR," scientists writing in the International Journal of Cancer report. "We postulated that FTS, a novel anti-Ras drug, could effectively inhibit hormone-dependent breast cancer because Ras activates both the MAP kinase and the PI3 kinase pathways. Wild-type MCF-7 cells and a...
Source: Women's Health Weekly (2005-12-29)
|
